Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape)

A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

Also called NCT01361425

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT01361425
Start date
(registry gives no type) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Unknown status (from the registry)

Technical summary

Registry record NCT01361425. Randomized; triple masking; primary purpose treatment. Start 2011-05 (registry gives no type); primary completion 2012-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape)
Acronym
METILDOPAPE
Condition
Preeclampsia
Intervention (Drug)
methildopa
Intervention (Drug)
placebo
Lead sponsor
Professor Fernando Figueira Integral Medicine Institute (class: other)
Collaborator
Conselho Nacional de Desenvolvimento Científico e Tecnológico (class: other government)

Record details

Record id
cardio:ct-nct01361425
Content hash
4abac111977a8d6216c9c7bf95c4511e675b7ff75ca77d80a34b04a92fcb502c